Citizens Reiterates Market Outperform Rating on Lyell Immunopharma (LYEL)
Tweet Send to a Friend
Citizens analyst Reni Benjamin reiterated a Market Outperform rating and $34.00 price target on Lyell Immunopharma (NASDAQ: LYEL).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


